Jin Yi, He Jun, Du Jing, Zhang Ru-Xuan, Yao Hai-Bo, Shao Qin-Shu
Department of General Surgery, Children's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310052, P.R. China.
Department of Gastroenterology and Pancreatic Surgery, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang 310014, P.R. China.
Oncol Lett. 2017 Nov;14(5):6191-6197. doi: 10.3892/ol.2017.6944. Epub 2017 Sep 14.
The purpose of the present study was to investigate the clinical significance of the expression of heparan sulfate 6-O-sulfotransferase 2 (HS6ST2) in gastric cancer (GC). The Affymetrix GeneChip Human Genome U133 Plus 2.0 Array (Affymetrix; Thermo Fisher Scientific, Inc., Waltham, MA, USA) was used to identify differentially expressed genes in GC tissues vs. adjacent non-tumor gastric tissues. Candidate genes were further verified by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and immunohistochemistry (IHC). In addition, an independent dataset was obtained from the Gene Expression Omnibus, and a survival analysis was performed. Microarray analysis demonstrated that was upregulated (>12-fold) in GC tissues compared with that in adjacent non-tumor tissues. RT-qPCR and IHC analysis of in GC tissues and adjacent non-tumor tissues confirmed the microarray data. Furthermore, a positive association was demonstrated between overexpression with the depth of tumor invasion, distant metastasis, and tumor-node metastasis stage. Survival analysis revealed an association between patients with increased expression of and a poor prognosis of gastric cancer. Cox regression analysis indicated that the expression of was an independent negative prognostic factor for GC. The expression of in GC was significantly associated with specific clinicopathological parameters and prognosis of disease, thus we propose that HS6ST2 may represent a novel biomarker for GC.
本研究的目的是探讨硫酸乙酰肝素6 - O -磺基转移酶2（HS6ST2）在胃癌（GC）中的表达的临床意义。使用Affymetrix基因芯片人类基因组U133 Plus 2.0阵列（Affymetrix；美国马萨诸塞州沃尔瑟姆市赛默飞世尔科技公司）来鉴定胃癌组织与相邻非肿瘤胃组织中差异表达的基因。候选基因通过逆转录定量聚合酶链反应（RT-qPCR）和免疫组织化学（IHC）进一步验证。此外，从基因表达综合数据库获得一个独立数据集，并进行生存分析。微阵列分析表明，与相邻非肿瘤组织相比，胃癌组织中[基因名称未给出]上调（>12倍）。对胃癌组织和相邻非肿瘤组织中[基因名称未给出]的RT-qPCR和IHC分析证实了微阵列数据。此外，[基因名称未给出]过表达与肿瘤浸润深度、远处转移和肿瘤-淋巴结转移分期之间呈正相关。生存分析显示，[基因名称未给出]表达增加的患者与胃癌预后不良相关。Cox回归分析表明，[基因名称未给出]的表达是胃癌的一个独立负性预后因素。胃癌中[基因名称未给出]的表达与特定的临床病理参数和疾病预后显著相关，因此我们提出HS6ST2可能代表一种新的胃癌生物标志物。
